PMID- 29763720
OWN - NLM
STAT- MEDLINE
DCOM- 20190506
LR  - 20201218
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 79
DP  - 2018 Sep
TI  - BAP1 loss is unusual in well-differentiated papillary mesothelioma and may 
      predict development of malignant mesothelioma.
PG  - 168-176
LID - S0046-8177(18)30158-8 [pii]
LID - 10.1016/j.humpath.2018.05.001 [doi]
AB  - Literature on BRCA1-associated protein 1 (BAP1) expression status in 
      well-differentiated papillary mesothelioma (WDPM) is limited. In the present 
      study, we examined the prevalence of BAP1 loss in WDPM by immunohistochemistry 
      with clinical correlation, along with CDKN2A deletion status by fluorescence in 
      situ hybridization (FISH). Eight patients diagnosed as having WDPM were 
      identified from the surgical pathology file. Adenomatoid tumors (n = 8) and 
      malignant mesothelioma (MM) (n = 39) were included for comparison. BAP1 
      immunohistochemistry was performed on representative block(s) from each case. 
      CDKN2A FISH was also performed in the WDPMs and adenomatoid tumors. Clinical 
      information was obtained from the medical records. Three of 8 WDPM patients 
      showed synchronous or metachronous MM. All 3 cases showed BAP1 loss in both WDPM 
      and the matched MM. Single-nucleotide polymorphism genomic microarray (n = 3) 
      demonstrated a similar genetic profile in the WDPM and MM components, which 
      supports their clonal relationship. The remaining 5 WDPM cases had intact BAP1 
      expression and had no evidence of disease on follow-up imaging studies at 1 to 
      71 months (median, 35 months). All 8 adenomatoid tumors had intact BAP1 
      expression, whereas 17 of 39 MM had BAP1 loss. CDKN2A FISH was negative for 
      deletion in 4 WDPMs tested (including the case that developed MM) and all 8 
      adenomatoid tumors. In our study, WDPM did not show CDKN2A deletion in any case. 
      BAP1 loss was also absent in all pure WDPM cases but was identified in all WDPM 
      with synchronous or metachronous MM. Similar genetic landscape in WDPM and MM 
      components suggested their clonal relationship.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Lee, Hee Eun
AU  - Lee HE
AD  - Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Molina, Julian R
AU  - Molina JR
AD  - Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Sukov, William R
AU  - Sukov WR
AD  - Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA; Division 
      of Molecular Genetics, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Roden, Anja C
AU  - Roden AC
AD  - Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Yi, Eunhee S
AU  - Yi ES
AD  - Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA. Electronic 
      address: Yi.Joanne@mayo.edu.
LA  - eng
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
DEP - 20180512
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (BAP1 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDKN2A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.4.19.12 (Ubiquitin Thiolesterase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Case-Control Studies
MH  - *Cell Differentiation
MH  - Cyclin-Dependent Kinase Inhibitor p16/genetics
MH  - Down-Regulation
MH  - Female
MH  - Gene Deletion
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*enzymology/genetics/pathology/therapy
MH  - Male
MH  - Mesothelioma/*enzymology/genetics/pathology/therapy
MH  - Mesothelioma, Malignant
MH  - Middle Aged
MH  - Neoplasms, Multiple Primary
MH  - Neoplasms, Second Primary
MH  - Phenotype
MH  - Polymorphism, Single Nucleotide
MH  - Tumor Suppressor Proteins/*analysis/genetics
MH  - Ubiquitin Thiolesterase/*analysis/genetics
OTO - NOTNLM
OT  - BAP1
OT  - CDKN2A
OT  - Malignant mesothelioma
OT  - Single-nucleotide polymorphism genomic microarray
OT  - Well-differentiated papillary mesothelioma
OT  - p16
EDAT- 2018/05/16 06:00
MHDA- 2019/05/07 06:00
CRDT- 2018/05/16 06:00
PHST- 2017/11/21 00:00 [received]
PHST- 2018/05/01 00:00 [revised]
PHST- 2018/05/02 00:00 [accepted]
PHST- 2018/05/16 06:00 [pubmed]
PHST- 2019/05/07 06:00 [medline]
PHST- 2018/05/16 06:00 [entrez]
AID - S0046-8177(18)30158-8 [pii]
AID - 10.1016/j.humpath.2018.05.001 [doi]
PST - ppublish
SO  - Hum Pathol. 2018 Sep;79:168-176. doi: 10.1016/j.humpath.2018.05.001. Epub 2018 
      May 12.